79 related articles for article (PubMed ID: 32968957)
1. Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC).
Alabd A; Alabd A; Bolaji O; Sugumar K; Ammori J; Hardacre J; Winter JM
Ann Surg Oncol; 2021 Feb; 28(2):1060-1068. PubMed ID: 32968957
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC).
Kamarajah SK; Bundred JR; Alrawashdeh W; Manas D; White SA
HPB (Oxford); 2020 May; 22(5):649-659. PubMed ID: 31894014
[TBL] [Abstract][Full Text] [Related]
3. Improvement of survival after surgical resection of pancreatic cancer independent of adjuvant chemotherapy in the past two decades - A meta-regression.
Weniger M; Miksch RC; Maisonneuve P; Werner J; D'Haese JG
Eur J Surg Oncol; 2020 Aug; 46(8):1516-1523. PubMed ID: 32204936
[TBL] [Abstract][Full Text] [Related]
4. Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized Study.
Chiu YF; Liu TW; Shan YS; Chen JS; Li CP; Ho CL; Hsieh RK; Hwang TL; Chen LT; Ch'ang HJ;
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):74-86. PubMed ID: 37055279
[TBL] [Abstract][Full Text] [Related]
5. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
[TBL] [Abstract][Full Text] [Related]
6. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
[TBL] [Abstract][Full Text] [Related]
7. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
[TBL] [Abstract][Full Text] [Related]
8. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
9. TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer.
Guenther M; Surendran SA; Haas M; Heinemann V; von Bergwelt-Baildon M; Engel J; Werner J; Boeck S; Ormanns S
Br J Cancer; 2023 Jul; 129(1):175-182. PubMed ID: 37142730
[TBL] [Abstract][Full Text] [Related]
10. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
11. High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial.
Pen SL; Shan YS; Hsiao CF; Liu TW; Chen JS; Ho CL; Chou WC; Hsieh RK; Chen LT; Ch'ang HJ
Radiother Oncol; 2021 May; 158():146-154. PubMed ID: 33667587
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis.
Parmar A; Chaves-Porras J; Saluja R; Perry K; Rahmadian AP; Santos SD; Ko YJ; Berry S; Doherty M; Chan KKW
Crit Rev Oncol Hematol; 2020 Jan; 145():102817. PubMed ID: 31955005
[TBL] [Abstract][Full Text] [Related]
13. Early versus delayed initiation of adjuvant treatment for pancreatic cancer.
Kim HW; Lee JC; Lee J; Kim JW; Kim J; Hwang JH
PLoS One; 2017; 12(3):e0173960. PubMed ID: 28301556
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Flaum N; Hubner RA; Valle JW; Amir E; McNamara MG
J Surg Oncol; 2019 Jun; 119(7):932-940. PubMed ID: 30838647
[TBL] [Abstract][Full Text] [Related]
16. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
[TBL] [Abstract][Full Text] [Related]
17. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
[TBL] [Abstract][Full Text] [Related]
18. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
Sonbol MB; Firwana B; Wang Z; Almader-Douglas D; Borad MJ; Makhoul I; Ramanathan RK; Ahn DH; Bekaii-Saab T
Cancer; 2017 Dec; 123(23):4680-4686. PubMed ID: 28817187
[TBL] [Abstract][Full Text] [Related]
19. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
20. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
